資訊推薦

• Questions 186~190 refer to the following text message, form, and email.From: Molly McDonaldReceived:
• 【題組】187.What problem did Molly McDonald encounter?(A) Her employee card didn’t work when she started
• 【題組】188.Why should Form No.9801 be submitted?(A) To gain control of the company.(B) To use an entran
• 【題組】189.How was Molly’s issue resolved that night?(A) Ivy went to the company and helped Molly in pe
• 【題組】190.What is true about the incident?(A) Molly got a new employee an hour after she successfully
• 65.某藥四種劑型之 72 小時尿中原型藥物排出量，如下表所示，何者之絕對生體可用率最小？ (A)靜脈注射溶液 (B)口服溶液 (C)口服膠囊 (D)口服錠劑
• Questions 191~195 refer to the following email, quotation, and invitation card.To: Samuel Stocking＜i
• 7.下列放射性藥物何者較常使用親電性氟化反應機制進行標幟下列放射性藥物何者較常使用親電性氟化反應機制進行標幟？(A) (B) (C) (D)
• 【題組】12. Consider the Red-Black tree resulting from sequentially inserting the following numbers into
• 【題組】13. Consider the B-tree, say T', resulting from sequentially inserting thefollowing numbers
• 【題組】14. Consider the B+-tree, say T', resulting from sequentially inserting thefollowing number
• 7. 已知等比數列 ＜an＞中，若a3 × a6＝3，則a1 × a2 × a3× a4 × a5 × a6 × α7 x a8 ＝(A)27(B)63(C)81(D)243
• 66.有關生體可用率之敘述，下列何者最適當？(A)用以衡量藥品在體內分布代謝的程度 (B)會受劑型之製劑配方或製程改變而影響 (C)須從特定疾病群組的受試者所得到的藥動參數 (D)相同藥品不同劑量會得
• 67.依據中華藥典，有關溶離圖比對（dissolution profile comparison）應用之敘述，下列何者錯誤？(A)可用以佐證藥物許可上市後變更（SUPAC）新配方藥品之相等性 (B)用
• 68.依中華藥典及 USP-NF，下列何者是一般錠劑與膠囊劑進行溶離試驗時最常用的溶離裝置？(A)Apparatus I/ Apparatus II (B)Apparatus I/ Apparatus
• 69.某原廠藥及學名藥具藥劑相等性，當學名藥之吸收程度低於原廠藥時，下列學名藥之相關數據可能變化，何者錯誤？ (A)最高血中濃度值下降 (B)尿中累積最大排除量下降 (C)達尿中累積最大排除量之時間延
• 70.根據 biopharmaceutics classification system（BCS）與 biopharmaceutics drug disposition classification
• 71.某藥物的最大代謝速率 Vmax 為 20 mg/L．hr，當濃度為 3 mg/L 時，代謝速率為 10 mg/L．hr 。則此藥之 KM 為若干 mg/L？ (A)1 (B)3 (C)5 (D)
• 72.下列何種情況最可能造成藥物發生非線性藥動學特性？(A)藥物蛋白結合率高 (B)藥物溶解度佳 (C)藥物排除速率快 (D)藥物吸收率佳
• 15. Consider the given directed graph. Let dist(i, j)be the length of the shortest path from node i
• 8. 已知△ABC中， ，則 長為 (A)7(B)10(C)12(D)14
• 73.已知某藥在人體內之排除遵循 Michaelis-Menten 動力學，其最大排除速率 為 300 mg/day，與血漿蛋白未結合分率為 0.4。當以 150 mg/day 的速率給與病人，得到穩
• 16. Consider the graph in the previous problem. Let dist(i, j) be the length of the shortest path fr
• 76.下列何者是經由鼻腔噴霧給藥的neuraminidase抑制劑？(A) (B) (C) (D)
• 17. Consider the following activity network. What is the length of the critical path? (A)14 (B) 16 (